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wMyocardial perfusion imaging (MPI) in acute myo-
cardial infarction (MI) has had its ups and downs
over the past 4 decades (1). “Cold-spot” imaging
with thallium-201, technetium-99m tetrofosmin
and sestamibi, wall motion assessment with gated
radionuclide angiography, and “hot-spot” imaging
with radionuclide-bound pyrophosphate, glucarate,
antimyosin, annexin V (2), and more recently,
duramycin (to target phosphatidylethanolamine)
(3) have focused on diagnosis and are now seldom
used because of the availability of sensitive bio-
markers. In the current era, MPI risk-stratifies
patients presenting to emergency departments with
chest pain and intermediate probability for acute
coronary syndrome (4), and assesses infarct size
after acute MI and myocardial salvage after coro-
nary revascularization (1).
See page 358
For patients presenting to emergency depart-
ments with chest pain, studies have suggested
benefit from imaging with various modalities in-
cluding MPI, 2-dimensional echocardiography,
magnetic resonance imaging (MRI), and computed
tomography (5). Myocardial salvage has mostly
been done with MPI and more recently MRI. The
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research grant from Astellas Pharma.tudy by Hadamitzky et al. (6) provides the largest
omparison to date between the 2 methods. The
uthors measured the area at risk (AAR) and scar in
atients with ST-segment elevation myocardial in-
arction (STEMI) (n  121) and non–ST-segment
levation myocardial infarction (NSTEMI) (n 
9) with MPI and MRI. The initial MPI was done
efore percutaneous coronary intervention (PCI)
to measure AAR). The second MPI scan (to
easure scar) and MRI were scheduled to occur at
to 7 days after PCI but were performed earlier
interquartile range [IQR]: 3.6 to 4.9 days for MRI;
ime between MRI and MPI 1.4 to 25.1 h). The
AR and scar by MPI were measured using auto-
ated analysis of polar maps (50% threshold of
egional tracer activity to define abnormal perfu-
ion). With MRI, AAR was assessed using a
2-weighted turbo spin echo sequence acquired
efore contrast injection whereas scar was assessed
5 min after injection of contrast agent on T1-
eighted inversion-recovery turbo fast low-angle
hot sequence.
Hadamitzky et al. (6) concluded that assessment
f AAR by MRI correlates well with MPI (r 
.80, p  0.0001). A reasonable correlation was
ound for salvage area (AAR  scar) (r  0.66).
verall, the salvage area by MRI was significantly
maller than by MPI. In 38% of patients, results
f both methods diverged by 10% of left
entricular volume (salvage area smaller in 25%
nd larger in 13% by MRI than MPI), a differ-
nce that may be clinically significant. The scar
ize was slightly larger by MRI, which could be
xplained by higher spatial resolution of MRI
esulting in detection of small subendocardial
cars missed by MPI.
The authors point out that MRI is not associated
ith potentially harmful radiation exposure and
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371contrast, MPI requires pre- and post-PCI scans.
Nevertheless, MRI has drawbacks of its own. It is
relatively contraindicated in patients with pacemak-
ers and defibrillators, and hard to perform in those
who suffer from claustrophobia. Thus, in this study
of 441 patients who had MPI for assessment of
myocardial salvage, 8% were ineligible for MRI due
to renal function or presence of pacemaker/
defibrillator, and 45% did not have an MRI for
various reasons, including lack of consent by patient
due to claustrophobia and logistical problems in
scheduling MRI before discharge. Also, because the
T2-weighted turbo spin echo sequence has a low
contrast-to-noise ratio, it requires a low threshold
of 2 SD for edema detection, which makes it
vulnerable to artifacts. The microvascular obstruc-
tion area was delineated manually, again introduc-
ing the possibility of measurement error with clinical
application. Further, in patients with tachycardia, ar-
rhythmia, pleural effusion, and heart failure, all
common, particularly after large infarctions, image
quality is suboptimal, and valid image analysis may
not be possible. In the current study, the exclusion
rate of 13% because of insufficient image quality
reflects these limitations in an experienced, con-
trolled setting. What these rates will translate to in
community practice is unknown. Thus, although
MRI may offer an alternative to MPI for myo-
cardial salvage assessment, contraindications of
this modality and limitations in the currently
established imaging sequences may cause a con-
siderable rate of data loss, which prevents wide-
spread clinical applicability.
It is interesting that in this study, 50% of patients
with STEMI and 59% with NSTEMI had Throm-
bolysis In Myocardial Infarction flow grade 0
before PCI, and yet they had detectable AAR
(often large). Despite coronary revascularization
with PCI, most patients had scar (14.7  16.9% of
eft ventricle), and there was no correlation between
ime from symptom onset to coronary revascular-
zation and myocardial salvage. The median time
etween symptom onset and PCI was 4.9 h in
TEMI (IQR: 3.4 to 8 h) and 12.6 h in NSTEMI
IQR: 8.4 to 23.6 h); the door-to-balloon time was
ot stated. These studies therefore do not negate
he possibility that earlier reperfusion might have
esulted in a more complete salvage. Alterna-
ively, imaging 2 to 4 weeks rather than 5 days
fter the index MI/PCI may have yielded differ-
nt results because the processes of metabolic
tunning, microvascular reperfusion, and myocar- Mial remodeling may be active beyond the first
ew days of an MI (7).
The time delay between symptom onset and
eperfusion suggests that measured AAR may have
ncluded myocardium that had already infarcted
nd was beyond salvage. It is possible that the AAR
ay have been exaggerated in some patients who
ad an initial perfusion abnormality (which later
esolved) despite the presence of antegrade flow
efore PCI. This is not unlike the well-documented
ituation seen in patients with rest MPI perfusion
efects after subsidence of chest pain resolution of
T changes (8). This phenomenon is probably
elated to complex kinetics of sestamibi, which is
ore than a “pure flow tracer.” It is important to
emember that the uptake mechanism of sestamibi
s dependent on the mitochondrial electromagnetic
radient, which is susceptible to metabolic derange-
ents that are initiated by ischemia (9). The
schemia cascade with emphasis on state of the
yocardium rather than conduit arteries is yet
nother explanation for dissociation of vessel pa-
ency and perfusion/cell edema patterns.
The correlations between MPI and MRI mea-
urements with functional data such as left ven-
ricular volumes and ejection fraction, although
ignificant, are modest. This is not unexpected
ecause these variables are load dependent, and
ontractility in remote myocardium is variable,
epending on myocardial blood flow, load con-
ition, associated diseases, medications, and re-
odeling (10). It is the less-than-perfect corre-
ation between perfusion and function that
xplains the additive prognostic value of these
ariables (11). Regrettably, prognostic data were
ot provided in this study. Also not provided are
epeatability data for MPI and MRI. These data
re important for sample size calculations for
uture studies. Despite the significant correlations
etween the 2 modalities, the Bland-Altman
lots show wide limits of agreement for measure-
ent of AAR, scar, and salvage area, and there-
ore, these modalities should not be used inter-
hangeably on serial testing.
The authors should be congratulated for provid-
ng correlative data on a large sample size, especially
ince assessment of AAR is not routinely done for
linical care. Promising developments in MRI tech-
ology could allow for assessment of increasing
roportion of patients and improve image quality to
ecrease the number of inadequate studies. Newer
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372tabolism and allow for measurement of myocardial
blood flow in target and remote zones may further
improve our understanding of AAR, hibernation,
stunning, and scar in vulnerable patients with acutepresenting to the emergency depart- technetium(I) in cuReprint requests and correspondence: Dr. Ami E. Iskan-
rian, Division of Cardiovascular Diseases, University of
labama at Birmingham, 318 LHRH, 1900 University
LVS, Birmingham, Alabama 35294. E-mail: aiskand@coronary syndrome. uab.edu.i
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